Senseonics announced that its one‑year continuous glucose monitor, Eversense 365, achieved a mean glucose management indicator of 7.14 % and a mean time‑in‑range of 66 % during a real‑world study of 5,059 U.S. sensors presented on March 14 at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2026). The data, collected over a full year of sensor wear, confirm the device’s long‑term accuracy and reliability, with 93.8 % of the sensor wear time maintained without interruption.
The study’s results build on earlier data from the same cohort, showing a steady improvement in glucose control over the first 12 months. Compared with the 10‑ to 14‑day CGM market, Eversense 365’s year‑long wear time eliminates the need for frequent sensor replacements, reducing patient burden and potentially improving adherence. The 66 % time‑in‑range figure is comparable to the best short‑term CGMs, while the 7.14 % GMI aligns with the target range for many patients with type 1 and type 2 diabetes.
From a business perspective, the evidence supports Senseonics’ strategy to expand its commercial footprint in the U.S. and Europe. The company’s CE Mark approval in January 2026 and the integration of Eversense 365 with Sequel’s twiist™ automated insulin delivery system—demonstrated in a subset of 120 patients with a 6.79 % GMI and 77 % time‑in‑range—position the product as a unique, year‑long solution that could capture market share from shorter‑wear CGMs. The data also reinforce the company’s revenue guidance for 2026, which has been raised to $58–$62 million from $54–$58 million, reflecting confidence in continued demand.
Management highlighted that the real‑world evidence underpins the company’s transition to a direct‑commercial model in the U.S. and Europe, which is expected to improve gross margins. CFO Frederick Sullivan noted that the company expects full‑year 2026 net revenue of approximately $58 million to $62 million, a 65 % to 76 % year‑over‑year increase, while acknowledging that significant investment is required to support this growth. CEO Tim Goodnow emphasized that the CE Mark approval and the AID integration are key drivers of the company’s expansion strategy.
Investors reacted to the Q4 2025 earnings release with concern over the company’s continued net loss of $69.1 million and the planned investment in 2026, which tempered enthusiasm for the positive clinical data presented at ATTD. The market’s focus on profitability and future capital needs highlights the importance of the real‑world evidence in validating the product’s commercial viability, even as investors weigh the company’s financial trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.